|
Prior to joining MPM in 1999, Mr. Wheeler was Chairman and CEO of InControl, Inc., a publicly traded medical device company that designed, developed, and marketed implantable medical devices to treat irregular heart rhythms. In September 1998, Mr. Wheeler negotiated the sale of InControl to Guidant Corporation. He serves on the Board of Directors of CryoCor, IntraTherapeutics, Intellicardia, Intraluminal Therapeutics, Scout Medical, Vidamed, Xoft MicroTube, and Optiscan Biomedical, where he is Chairman. Previously, he was on the Board of Heartstream, which was acquired by Hewlett Packard. Prior to InControl, Mr. Wheeler was a principal in the life science group at the Mayfield Fund, a venture capital partnership. He has participated in the early stage development of several biotechnology companies including Sungene Technologies, Affymax NV, and Cell Genesys. He began his professional career at Eli Lilly & Co. He holds a B.A. degree from Brigham Young University and a M.B.A. degree from Northwestern University, where he serves on the Kellogg Alumni Advisory Board.
| 